Products
Gruticibart Biosimilar Monoclonal Antibody (Factor XI) for Research
Cat No.: GMP-Bios-INN-1224
Anti-F11 therapeutic antibody (Pre-made Gruticibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gruticibart (development code AB-023) is a monoclonal antibody targeting coagulation factor XI (F11). It is developed by Oregon Health & Science University and Aronora for thrombosis. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1224-1mg | 1mg | 3090 |
| GMP-Bios-INN-1224-10mg | 10mg | |
| GMP-Bios-INN-1224-100mg | 100mg | |
| GMP-Bios-INN-1224-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gruticibart biosimilar, Whole mAb, Anti-F11 Antibody: Anti-F11/Coagulation factor XI/FXI/Plasma thromboplastin antecedent (PTA) therapeutic antibody |
| INN Name | Gruticibart |
| Target | F11 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Oregon Health & Science University;Aronora |
| Conditions Approved | na |
| Conditions Active | Thrombosis |
| Conditions Discontinued | Cardiovascular disorders;Neurological disorders;Sepsis |
| Production | na |
| Development Tech | na |
